C12Y 304/22044
Nuclear-inclusion-a endopeptidase
Official title: Nuclear-inclusion-a endopeptidase (3.4.22.44)
C12Y304/22044 (Nuclear-inclusion-a endopeptidase) appears on 25 US grants and 55 published applications in this corpus.
Search patents in C12Y- Granted patents
- 25
- Published applications
- 55
- Assignees
- 43
- Inventors
- 114
- Latest grant
- 19 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 0 | 1 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 1 |
| 2009 | 1 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 1 |
| 2012 | 1 | 1 |
| 2013 | 1 | 2 |
| 2014 | 0 | 1 |
| 2015 | 1 | 1 |
| 2016 | 1 | 3 |
| 2017 | 1 | 1 |
| 2018 | 0 | 4 |
| 2019 | 1 | 3 |
| 2020 | 2 | 2 |
| 2021 | 2 | 2 |
| 2022 | 3 | 8 |
| 2023 | 3 | 8 |
| 2024 | 3 | 6 |
| 2025 | 3 | 4 |
| 2026 | 2 | 6 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- TEV protease with dual affinity tags19 May 2026US 12,630,813 B2AbClonal Science, Inc.
- Directed evolution for obtaining improved variants of TEV protease for biotechnological applications31 Mar 2026US 12,590,325 B2CZ Biohub SF, LLC
- Method for robust control of gene expression13 May 2025US 12,297,236 B2California Institute of Technology
- Method for screening protease variant and obtained protease variant8 Apr 2025US 12,270,124 B2Shangrao Concord Pharmaceutical Co., Ltd.
- Selective cell death-inducing enzyme system4 Feb 2025US 12,214,011 B2
- Intracellular Delivery of Therapeutic Cargos and Viral RNAS by Engineered Salmonella17 Sep 2026US 2026/0272995 A1The Trustees of Columbia University in the City of New York
- Cold-active tev proteases, compositions and methods13 Aug 2026US 2026/0234592 A1New England Biolabs, Inc.
- Expression of modified proteins in a peroxisome13 Aug 2026US 2026/0234647 A1The Regents of the University of California
- System For Modulating Receptor Tyrosine Kinase Signaling And Methods Of Use Thereof9 Jul 2026US 2026/0193634 A1The Johns Hopkins University
- Gene editing systems and methods for reducing immunogenicity and graft versus host response4 Jun 2026US 2026/0152740 A1Correctsequence Therapeutics (Shanghai) Co., Ltd
Most cited
By later US patents
- Bimolecular protease-based biosensor11US 9,772,328 B2The University of Queensland · 2017
- Processing of a modified foot-and-mouth disease virus P1 polypeptide by an alternative protease3US 10,308,927 B2The United States of America, as represented by the Secretary of Homeland Security · 2019
- Nanopatterned extracellular matrices enable cell-based assays with a mass spectrometric readout3US 10,563,244 B2Northwestern University · 2020
- Mutant proteinase with reduced self-cleavage activity and method of purification3US 7,494,786 B2Yale University · 2009
- Inhibition of unintended mutations in gene editing2US 11,384,353 B2Shanghaitech University · 2022